AtriCure, Inc. (NASDAQ: ATRC) recently announced the receipt of an expanded indication for the AtriClip in CE-marked countries in Europe. The product is now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted. The European Commission’s expanded indication is based on AtriCure’s clinical findings that patients who are at high risk of thromboembolism can experience fewer strokes with AtriClip.The company expects significant growth potential for the use of mechanical appendage closure. More on the NewsThe LAA is a major source …